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HDD cannot be advocated for all patients
Sir,
Saner and colleagues have made a good case for home
haemodialysis (HHD) as an effective renal replacement
therapy in Switzerland [1]. Yet, in the last paragraph
of their case–cohort study of 58 patients, they admit
that patient selection may have inﬂuenced their results. We
agree. Our analysis of a much larger cohort, that of the
United States Renal Data System, used the standardized
mortality ratio (SMR) to compare HHD patients with
in-centre haemodialysis patients. The SMR takes age, race,
gender and diabetes into account. Contrary to older reports,
we found that HHD had a higher SMR compared with
in-centre dialysis (see Table 1) [2].
In addition, the cost of HHD was not cheap, while
somewhat less than in-centre dialysis, which was $54 917 per
year over the same time of study.
Our data run counter to accepted wisdom about HHD.
Increasing patient co-morbidity, decreasing family support
and waning of doctor and nurse expertise may explain the
inferior HHD outcomes in the USA. It is also likely that
in-centre dialysis has improved its dialysis delivery to a
greater extent than has HHD in recent years.
HHD cannot be advocated for all patients. Even the still-
infrequent newer daily HHD therapies will require scrutiny
and proper outcome analysis.
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Reply
Sir,
Cohen and Charba challenge the results of our study by
presenting an alternative cohort from the United States Renal
Data System (USRDS) that shows a higher standardized
mortality rate (SMR) for home haemodialysis patients
compared with in-centre patients.
We have discussed the possibility of a selection bias
in our small cohort. Patient selection might also have
inﬂuenced the ﬁndings of the USRDS registry, despite
the much larger number of patients accumulated. The
mortality rates of the USRDS patients were standardized
according to age, race, gender and diabetes. No data are
given about social status, regional distribution and access
to medical facilities. Furthermore, it is unknown if dialysis
treatment parameters, the amount of dialysis delivered
and the percentage of ﬁlter reuse were the same at home as
in the centre.
Switzerland is small and has a high density of dialysis
units so that home haemodialysis is rarely selected on
the basis of poor access to medical facilities. The advantage
of our small single centre cohort is that home haemo-
dialysis patients had comparable dialysis prescriptions and
used the same materials as those treated in-centre.
Furthermore, they were followed by the same medical staff
as the in-centre patients.
We have reasons enough to continue convincing and
training home haemodialysis patients. However, we have to
ensure that the patients treated at home are not deprived
of advances in renal replacement therapy.
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Table 1.
Year No. of HHD % of all
dialysis
Cost/year (US$)
for HHD
SMR
1998 1676 0.7 44 160 1.19
1999 1327 0.5 43 304 1.09
2000 1444 0.5 42 326 1.38
2001 1338 0.5 47 554 1.37
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